ABVX:NASDAQ
Abivax SA
$118.64
arrow_upward
+2.32%(+2.69) 1D
$115.54
arrow_downward
-2.61% (-3.10)todayPre-market
Closed: Sep 11, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
$115.46
High
$119.02
Low
$114.68
Mkt. cap
8.73B
Avg. vol.
929.05K
Volume
1.32K
52-wk high
$148.83
52-wk low
$69.81
Shares outstanding
87.35M
No. of employees
80
Open
$115.46
High
$119.02
Low
$114.68
Mkt. cap
8.73B
Avg. vol.
929.05K
Volume
1.32K
52-wk high
$148.83
52-wk low
$69.81
Shares outstanding
87.35M
No. of employees
80
News stories
From web sources and news partners
scanx.trade
·
39 minutes ago
Abivax H1FY26 Results: Loss expected at $1.08 per share
Benzinga
·
1 hour ago
Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
MarketBeat
·
4 hours ago
Abivax (ABVX) Projected to Post Quarterly Earnings on Monday
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees80
FoundedDec 4, 2013
Headquarters-
SectorBiotechnology
Websiteabivax.com